Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020 , at 4:30 p.m. ET HOUSTON , May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq:

HOUSTON , May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced today that an abstract on the Phase 1/2 clinical trial of seclidemstat in Ewing sarcoma has been

Conference Call and Live Audio Webcast Scheduled for Thursday, May 14, 2020 at 4:30 p.m. ET HOUSTON , May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that

Board of Directors Seeks the Election of Jonathan Lieber, Industry Veteran with Deep Financial and Wall Street Expertise, as a New, Independent Director HOUSTON , April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting

HOUSTON , April 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief executive officer, David Arthur , will deliver a virtual presentation at the

Seclidemstat Achieves Dose-Escalation Milestone in Phase 1/2 Ewing Sarcoma Clinical Trial Sixth Level Dosing Cohort Now Proceeding; On Track To Report Topline Data in 2020 HOUSTON , March 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a clinical-stage biotechnology

European Patent Office Satisfied Patent Application Meets All Requirements Salarius’ Global Intellectual Property Estate Includes 22 Issued Patents in the U.S. , Europe and 12 Other Jurisdictions HOUSTON , March 04, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a

HOUSTON , March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief executive officer, David Arthur , will be attending the 30 th Annual Oppenheimer

HOUSTON , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the closing of its previously announced underwritten public offering, with total gross proceeds of

HOUSTON , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur , will present at the Noble Capital Markets’ 16